UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia

Boccardi, M; Festari, C; Altomare, D; Gandolfo, F; Orini, S; Nobili, F; Frisoni, GB; (2018) Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia. European Journal of Nuclear Medicine and Molecular Imaging , 45 (9) pp. 1470-1486. 10.1007/s00259-018-4024-1. Green open access

[thumbnail of Walker_00_Methods_Boccardi_Final.pdf]
Preview
Text
Walker_00_Methods_Boccardi_Final.pdf - Accepted Version

Download (1MB) | Preview

Abstract

BACKGROUND: FDG-PET is frequently used as a marker of synaptic damage to diagnose dementing neurodegenerative disorders. We aimed to adapt the items of evidence quality to FDG-PET diagnostic studies, and assess the evidence available in current literature to assist Delphi decisions for European recommendations for clinical use. METHODS: Based on acknowledged methodological guidance, we defined the domains, specific to FDG-PET, required to assess the quality of evidence in 21 literature searches addressing as many Population Intervention Comparison Outcome (PICO) questions. We ranked findings for each PICO and fed experts making Delphi decisions for recommending clinical use. RESULTS: Among the 1435 retrieved studies, most lacked validated measures of test performance, an adequate gold standard, and head-to-head comparison of FDG-PET and clinical diagnosis, and only 58 entered detailed assessment. Only two studies assessed the accuracy of the comparator (clinical diagnosis) versus any kind of gold-/reference-standard. As to the index-test (FDG-PET-based diagnosis), an independent gold-standard was available in 24% of the examined papers; 38% used an acceptable reference-standard (clinical follow-up); and 38% compared FDG-PET-based diagnosis only to baseline clinical diagnosis. These methodological limitations did not allow for deriving recommendations from evidence. DISCUSSION: An incremental diagnostic value of FDG-PET versus clinical diagnosis or lack thereof cannot be derived from the current literature. Many of the observed limitations may easily be overcome, and we outlined them as research priorities to improve the quality of current evidence. Such improvement is necessary to outline evidence-based guidelines. The available data were anyway provided to expert clinicians who defined interim recommendations.

Type: Article
Title: Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia
Open access status: An open access version is available from UCL Discovery
DOI: 10.1007/s00259-018-4024-1
Publisher version: https://doi.org/10.1007/s00259-018-4024-1
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: FDG-PET, Positron emission tomography, Fluorodeoxyglucose metabolism, 18F-FDG PET, Evidence assessment, Quality of evidence, Recommendations, Validation Biomarker, Alzheimer Dementia, Diagnosis
UCL classification: UCL
UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Division of Psychiatry
URI: https://discovery.ucl.ac.uk/id/eprint/10064435
Downloads since deposit
187Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item